Difference between revisions of "NK- and T-cell lymphoma - historical"
Jump to navigation
Jump to search
(Created page with "The purpose of this page is to provide references to regimens that are obsolete, outdated, or of historical interest only. As a general rule, this includes the inferior arm(s)...") |
Warner-admin (talk | contribs) m (Text replacement - "|NR" to "|Not reported") |
||
| (3 intermediate revisions by 2 users not shown) | |||
| Line 1: | Line 1: | ||
| − | The purpose of this page is to provide references to regimens that are obsolete, outdated, or of historical interest only | + | The purpose of this page is to provide references to regimens that are obsolete, outdated, or of historical interest only. Is there a regimen missing from this list? See the [[NK- and T-cell lymphoma|main NKTCL page]] for current regimens. |
{| class="wikitable" style="float:right; margin-right: 5px;" | {| class="wikitable" style="float:right; margin-right: 5px;" | ||
|- | |- | ||
| Line 8: | Line 8: | ||
=Relapsed or refractory= | =Relapsed or refractory= | ||
==Pembrolizumab monotherapy {{#subobject:84ac5y|Regimen=1}}== | ==Pembrolizumab monotherapy {{#subobject:84ac5y|Regimen=1}}== | ||
| − | <div class="toccolours" style="background-color:# | + | <div class="toccolours" style="background-color:#ee6b6e"> |
===Regimen {{#subobject:ga3na4|Variant=1}}=== | ===Regimen {{#subobject:ga3na4|Variant=1}}=== | ||
| − | {| class="wikitable" style="width: | + | {| class="wikitable sortable" style="width: 60%; text-align:center;" |
| − | !style="width: | + | !style="width: 33%"|Study |
| − | !style="width: | + | !style="width: 33%"|Dates of enrollment |
| + | !style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]] | ||
|- | |- | ||
|[https://doi.org/10.1182/blood-2016-12-756841 Kwong et al. 2017] | |[https://doi.org/10.1182/blood-2016-12-756841 Kwong et al. 2017] | ||
| + | |Not reported | ||
| style="background-color:#ffffbe" |Case series | | style="background-color:#ffffbe" |Case series | ||
|- | |- | ||
| Line 24: | Line 26: | ||
'''21-day cycles''' | '''21-day cycles''' | ||
</div></div> | </div></div> | ||
| + | |||
===References=== | ===References=== | ||
#Kwong YL, Chan TSY, Tan D, Kim SJ, Poon LM, Mow B, Khong PL, Loong F, Au-Yeung R, Iqbal J, Phipps C, Tse E. PD1 blockade with pembrolizumab is highly effective in relapsed or refractory NK/T-cell lymphoma failing l-asparaginase. Blood. 2017 Apr 27;129(17):2437-2442. Epub 2017 Feb 10. [https://doi.org/10.1182/blood-2016-12-756841 link to original article] [https://pubmed.ncbi.nlm.nih.gov/28188133/ PubMed] | #Kwong YL, Chan TSY, Tan D, Kim SJ, Poon LM, Mow B, Khong PL, Loong F, Au-Yeung R, Iqbal J, Phipps C, Tse E. PD1 blockade with pembrolizumab is highly effective in relapsed or refractory NK/T-cell lymphoma failing l-asparaginase. Blood. 2017 Apr 27;129(17):2437-2442. Epub 2017 Feb 10. [https://doi.org/10.1182/blood-2016-12-756841 link to original article] [https://pubmed.ncbi.nlm.nih.gov/28188133/ PubMed] | ||
Latest revision as of 11:00, 6 July 2024
The purpose of this page is to provide references to regimens that are obsolete, outdated, or of historical interest only. Is there a regimen missing from this list? See the main NKTCL page for current regimens.
1 regimens on this page
1 variants on this page
|
Relapsed or refractory
Pembrolizumab monotherapy
Regimen
| Study | Dates of enrollment | Evidence |
|---|---|---|
| Kwong et al. 2017 | Not reported | Case series |
Note: prospective trials are underway.
References
- Kwong YL, Chan TSY, Tan D, Kim SJ, Poon LM, Mow B, Khong PL, Loong F, Au-Yeung R, Iqbal J, Phipps C, Tse E. PD1 blockade with pembrolizumab is highly effective in relapsed or refractory NK/T-cell lymphoma failing l-asparaginase. Blood. 2017 Apr 27;129(17):2437-2442. Epub 2017 Feb 10. link to original article PubMed